Transition from serum-supplemented monolayer to serum-free suspension lentiviral vector production for generation of chimeric antigen receptor T cells-Reference-Cited by-同舟云学术

Transition from serum-supplemented monolayer to serum-free suspension lentiviral vector production for generation of chimeric antigen receptor T cells

Published:2022-08 Issue:8 Volume:24 Page:850-860
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Tirapelle Mariane Cariati^ORCID,Oliveira Lomba Ana Luiza,Silvestre Renata Nacasaki^ORCID,Mizukami Amanda,Covas Dimas Tadeu,Picanço-Castro Virgínia^ORCID,Swiech Kamilla^ORCID

Funder

Fundação de Amparo à Pesquisa do Estado de São Paulo

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference42 articles.

1. Imunoterapia com células T-CAR: bioengenharia contra a leucemia;Martho;Cuidarte Enfermagem,2017

2. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You;Ruella;Current Hematologic Malignancy Reports,2016

3. June, C. H. et al. CAR T cell immunotherapy for human cancer. Science, v. 359, n. 6382, p. 1361–1365, 2018.

4. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward;Li;Journal of Hematology and Oncology,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum-free lentiviral vector production is compatible with medium-resident nuclease activity arising from adherent HEK293T host cells engineered with a nuclease-encoding transgene;Heliyon;2023-06